Roche/Ipsen's antidiabetic passes two more Phase III studies
This article was originally published in Scrip
Executive Summary
Top-line data show that Roche/Ipsen's GLP-1 analogue, taspoglutide, was superior to Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) in one Phase III trial and superior to placebo in another. The drug has now passed the first three of its eight Phase III trials, including a head-to-head trial against Lilly/Amylin's Byetta (exenatide).